Neuroscience

#Neuroscience

Whitepaper – Navigating Neurological Biomarker Research: Progress, Learnings and Future Directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology.   Brought to… Read More

#Whitepapers

#Blood-based biomarkers #Neurodegenerative disorders #Neuroscience #Proteomics

How blood proteomics is accelerating neuro drug discovery

This article is sponsored by Standard BioTools. Neurodegenerative diseases affect more than 57 million people globally, a figure expected to double within two decades1,2. This alarming projection reflects three major clinical challenges: difficulty diagnosing disease in early, treatable stages; a lack of curative therapies; and limited treatment options2,3. Read More

#Exclusive Content

Drugs targeting amyloid Plaque
#Alzheimer's #Eli Lilly #European Commission #Neurodegenerative disorders #Neuroscience

European Commission extends EU use of Lilly’s donanemab

The European Commission (EC) has granted marketing authorisation for Lilly’s Kisunla (donanemab) in early symptomatic Alzheimer’s disease (AD).  It is approved in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes… Read More

#News #Regulatory

#Drug discovery #Funding #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Lys Therapeutics awarded $5m to advance neuro pipeline  

French biotech Lys Therapeutics has received a grant award of $5 million (£3.6 million) from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to accelerate the clinical development of its first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders.  The funding… Read More

#News

#Clinical trial #Drug discovery #Gene therapy #Neuroscience #Parkinson's

AskBio begins second phase of gene therapy trial for Parkinson’s  

The first European patients have been randomised in a Phase II gene therapy clinical trial for Parkinson’s disease (PD), AskBio has announced.   The REGENERATE-PD clinical trial is evaluating the safety and efficacy of AskBio’s investigational gene therapy AB-1005 and will enrol approximately 87 patients across clinical trial… Read More

#Editor's Choice #News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience

What’s next for dementia drug research and development? 

To mark World Alzheimer’s Day on 21 September, Drug Discovery World speaks to biotech companies and investors at the forefront of next-generation dementia drugs.  After years of trudging through something akin to a Slough of Despond, dementia researchers, clinicians and patients have finally been given something to… Read More

#Exclusive Content

#Digital biomarkers #Monument Therapeutics #National Institutes of Health (NIH) #Neuroscience #Schizophrenia

Monument Therapeutics partners on novel treatment for schizophrenia

Monument Therapeutics and the Foundation for the National Institutes of Health (FNIH) will evaluate MT1988, in development for cognitive impairment associated with schizophrenia, in a proof-of-principle clinical trial.  Many individuals begin to show signs of schizophrenia months or even years before receiving a diagnosis, referred to as… Read More

#Business & Investment #News

Neurons in Parkinson's disease
#Neuroinflammation #Neuroscience #NodThera #Parkinson's #Phase II trial

Oral NLRP3 inhibitor reverses neuroinflammation in Parkinson’s

NodThera has shared positive data from its Parkinson’s disease Phase Ib/IIa study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3 inflammasome inhibitor.  In the first publication to demonstrate the clinical potential of an oral, fully brain-penetrant NLRP3 inhibitor in Parkinson’s disease, NT-0796 was shown to be… Read More

#News

Neurons
#Alzheimer's #Neurodegenerative disorders #Neuroscience #Porosome Therapeutics

New Alzheimer’s therapy restores neurotransmission

Porosome Therapeutics has shared key advancements in its disease-modifying neurological platform, which it claims will transform Alzheimer’s Disease (AD) research and treatment by offering a new approach that goes beyond symptom management.   The company has demonstrated a relatively rapid reduction of the Alzheimer’s pathology in AD human… Read More

#News

Human brain
#Mergers and acquisitions #Neurodegenerative disorders #Neuroscience #Sanofi #Vigil Neuroscience

Sanofi completes acquisition of Vigil Neuroscience

Sanofi has completed its acquisition of Vigil Neuroscience, adding VG-3927, a novel, oral, small-molecule TREM2 agonist, to Sanofi’s neurology pipeline.  Vigil is a clinical-stage biotechnology company targeting neurodegenerative diseases through disease-modifying therapeutics that restore the vigilance of microglia.  Sanofi will also acquire Vigil’s preclinical pipeline… Read More

#Business & Investment #News

Human brain
#Drug discovery #Multiple sclerosis #Neurodegenerative disorders #Neuroscience

Does EBV trigger multiple sclerosis and drive its progression?

Evelyn Peelen, Head of Research, Andreas Muehler, Chief Medical Officer, and Hella Kohlhof, Chief Scientific Officer at Immunic Therapeutics discuss the unmet need for MS treatments that combine neuroprotective, anti-inflammatory, and antiviral properties. For a long time, multiple sclerosis (MS) has been viewed as a disease driven solely by peripheral… Read More

#Exclusive Content

Proteomics
#Alzheimer's #Collaboration #Nautilus Biotechnology #Neuroscience #Partnership #Proteomics

Nautilus forms partnership to better understand Alzheimer’s

Proteome analysis company Nautilus Biotechnology has announced a partnership with the Allen Institute focused on improving our understanding of neurodegenerative conditions.  The organisations will investigate the connection between the tau protein and its occurrence in neurodegenerative conditions such as Alzheimer’s disease.  Recent studies suggested that… Read More

#Business & Investment #News

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neuroscience

New DDW Highlights podcast: 4 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the Alzheimer’s Association International Conference (AAIC) taking place this week in Toronto, Canada, there… Read More

#News

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neuroscience

This week in drug discovery (28 July – 1 August) 

News round-up for 28 July – 1 August by DDW Senior Digital Content Editor Diana Turner. With the Alzheimer’s Association International Conference (AAIC) taking place this week in Toronto, Canada, there have been a number of updates in the neuroscience drug discovery field. The top stories:… Read More

#News

Older adult receiving vaccine
#Dementia #GSK #Immunology / Virology & Vaccines #Neuroscience #Shingles

RWD shows shingles vaccine reduces dementia risk

GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia.  Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More

#News #Trending News

#AltPep Corporation #Alzheimer's #Neuroscience #Peptides

Peptide for Alzheimer’s increases clearance of amyloid plaques

AltPep Corporation has presented new preclinical data on its lead compound, Soluble Oligomer Binding Inhibitor (SOBIN-AD), as a treatment for early Alzheimer’s disease (AD) at the Alzheimer’s Association International Conference (AAIC).   The preclinical data show SOBIN-AD:  Binds amyloid beta (Aβ) oligomers 27,000-fold stronger than… Read More

#News